BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate
Bristol Myers Squibb Will Handle Compound’s Clinical, Commercial Development
Bristol Myers Squibb will in-license an immune-modulating drug candidate created by AI-pioneer Exscientia, the first in their expanded multi-target alliance announced in May.
You may also be interested in...
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.